生物能学
细胞命运测定
生物
线粒体
癌症研究
细胞生物学
细胞凋亡
程序性细胞死亡
化疗
遗传学
基因
转录因子
作者
Charlotte Palominos,Sebastián Fuentes-Retamal,Juan Pablo Salazar,Daniela Guzmán‐Rivera,Pablo Correa,M Mellado,Ramiro Araya‐Maturana,Félix A. Urra
出处
期刊:Cancer Letters
[Elsevier BV]
日期:2024-05-22
卷期号:594: 216965-216965
被引量:11
标识
DOI:10.1016/j.canlet.2024.216965
摘要
Pro-survival BCL-2 proteins prevent the initiation of intrinsic apoptosis (mitochondria-dependent pathway) by inhibiting the pro-apoptotic proteins BAX and BAK, while BH3-only proteins promote apoptosis by blocking pro-survival BCL-2 proteins. Disruptions in this delicate balance contribute to cancer cell survival and chemoresistance. Recent advances in cancer therapeutics involve a new generation of drugs known as BH3-mimetics, which are small molecules designed to mimic the action of BH3-only proteins. Promising effects have been observed in patients with hematological and solid tumors undergoing treatment with these agents. However, the rapid emergence of mitochondria-dependent resistance to BH3-mimetics has been reported. This resistance involves increased mitochondrial respiration, altered mitophagy, and mitochondria with higher and tighter cristae. Conversely, mutations in isocitrate dehydrogenase 1 and 2, catalyzing R-2-hydroxyglutarate production, promote sensitivity to Venetoclax. This evidence underscores the urgency for comprehensive studies on bioenergetics-based adaptive responses in both BH3 mimetics-sensitive and -resistant cancer cells. Ongoing clinical trials are evaluating BH3-mimetics in combination with standard chemotherapeutics. In this article, we discuss the role of mitochondrial bioenergetics in response to BH3-mimetics and explore potential therapeutic opportunities through metabolism-targeting strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI